Comparative in vitro activity of gemifloxacin to other fluoroquinolones and non-quinolone agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States in 1999-2000

被引:11
作者
Koeth, LM
Jacobs, MR
Bajaksouzian, S
Zilles, A
Lin, GR
Appelbaum, PC
机构
[1] Lab Specialists Inc, Westlake, OH 44145 USA
[2] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA
[3] Univ Hosp Cleveland, Cleveland, OH 44106 USA
[4] Penn State Univ, Milton S Hershey Med Ctr, Dept Pathol, Hershey, PA 17033 USA
关键词
fluoroquinolone antimicrobial agents; Streptococcus pneumoniae; gemifloxacin;
D O I
10.1016/S0924-8579(01)00431-9
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
This study was undertaken to assess the in vitro activity of gemifloxacin, five other fluoroquinolone antimicrobial agents (ciprofloxacin, gatifloxacin, levofloxacin, moxifloxacin and ofloxacin) and other non-quinolone comparator agents (ampicillin, erythromycin, clindamycin, doxycycline, penicillin and trimethoprim/sulphamethoxazole) against Streptococcus pneumoniae collected in the United States. Susceptibility testing of 550 S. pneumoniae, 290 Haemophilus influenzae and 205 Moraxella catarrhalis showed that 38.2% of pneumococci were penicillin nonsusceptible, while 26,2 and 95.6% of H. influenzae and M. catarrhalis, respectively, produced beta-lactamase. Overall new fluoroquinolones were the most active agents. The in vitro activity (based on MIC90 in mg/l) of the six fluoroquinolones was gemifloxacin > moxifloxacin > gatifloxacin > levofloxacin > ciprofloxacin and ofloxacin. (C) 2002 Elsevier Science B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:33 / 37
页数:5
相关论文
共 15 条
[1]   IN-VITRO ACTIVITIES OF 12 ORALLY-ADMINISTERED ANTIMICROBIAL AGENTS AGAINST 4 SPECIES OF BACTERIAL RESPIRATORY PATHOGENS FROM US-MEDICAL-CENTERS IN 1992 AND 1993 [J].
BARRY, AL ;
PFALLER, MA ;
FUCHS, PC ;
PACKER, RR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (10) :2419-2425
[2]  
Bartlett John G., 2000, Clinical Infectious Diseases, V31, P347, DOI 10.1086/313954
[3]   Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada [J].
Chen, DK ;
McGeer, A ;
de Azavedo, JC ;
Low, DE .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (04) :233-239
[4]   Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America:: 1997 results from the SENTRY antimicrobial surveillance program [J].
Doern, GV ;
Pfaller, MA ;
Kugler, K ;
Freeman, J ;
Jones, RN .
CLINICAL INFECTIOUS DISEASES, 1998, 27 (04) :764-770
[5]   Acute otitis media:: management and surveillance in an era of pneumococcal resistance -: a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group [J].
Dowell, SF ;
Butler, JC ;
Giebink, GS ;
Jacobs, MR ;
Jernigan, D ;
Musher, DM ;
Rakowsky, A ;
Schwartz, B .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1999, 18 (01) :1-9
[6]  
Drusano GL, 1997, J CHEMOTHERAPY, V9, P38
[7]  
FLEMINGHAM D, 1996, J ANTIMICROB CHEM SA, V38, P1
[8]   Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters:: 1997 US surveillance study [J].
Jacobs, MR ;
Bajaksouzian, S ;
Zilles, A ;
Lin, GR ;
Pankuch, GA ;
Appelbaum, PC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (08) :1901-1908
[9]   In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: Data from the SENTRY antimicrobial surveillance program [J].
Jones, RN ;
Pfaller, MA .
CLINICAL INFECTIOUS DISEASES, 2000, 31 :S16-S23
[10]   ANTIMICROBIAL RESISTANCE AMONG RESPIRATORY ISOLATES OF HAEMOPHILUS-INFLUENZAE, MORAXELLA-CATARRHALIS, AND STREPTOCOCCUS-PNEUMONIAE IN THE UNITED-STATES [J].
JORGENSEN, JH ;
DOERN, GV ;
MAHER, LA ;
HOWELL, AW ;
REDDING, JS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (11) :2075-2080